Metastasiertes Mammakarzinom – zielgerichtete Therapie

Metastatic breast cancer is increasingly being treated on an individualized basis. In addition to traditional target structures such as the hormone receptor and HER2, therapies against BRCA1/2, PIK3CA, AKT, or ESR1 mutations are increasingly being used. The antibody–drug conjugate trastuzumab deruxtecan is effective not only in HER2-positive tumors but also in HER2-low tumors. Immune checkpoint inhibitors improve survival in advanced triple-negative breast cancer. An increase in survival in advanced breast cancer can now also be observed in routine care.